8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Mar 3, 2026·SEC
Evolus, Inc.(EOLS)Earnings, Financials & Key Ratios
EOLS•NASDAQ
$6.94
Price updated Jul 7, 2026
AboutEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Show more
- Revenue$297M+11.6%
- EBITDA-$29M-1.6%
- Net Income-$52M-2.4%
- EPS (Diluted)-0.80+1.2%
- Gross Margin64.86%-5.3%
- EBITDA Margin-9.71%+8.9%
- Operating Margin-12.65%+2.1%
- Net Margin-17.38%+8.2%
EOLS Price & Volume
Evolus, Inc. (EOLS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Challenge Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Single-product revenue concentration
Key Thesis Takeaways
- Evolus faces a precarious fundamental outlook as its single-product reliance on Jeuveau encounters significant competitive headwinds, evidenced by a deceleration in year-over-year revenue growth from 42.2% in 2024Q1 to 6.2% in 2026Q1.
- The company's inability to scale operating income, coupled with a shift to negative shareholder equity of -$28.8 million, suggests that the current high-cost marketing model is failing to achieve sustainable profitability.
- Investors should monitor the company's ability to manage its $156.4 million debt burden while navigating a market where gross margins remain structurally capped by third-party supply agreements.
Verdict Logic
the company's reliance on debt to fund operations, evidenced by a $156.4 million debt load and negative equity, suggests a high risk of further dilution or liquidity constraints.
EOLS Growth Metrics
Evolus, Inc. (EOLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years39.36%
3 Years25.98%
TTM9.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.94%
Return on Capital
10 Years-51.75%
5 Years-32.02%
3 Years-27.28%
Last Year-23.49%
EOLS Recent Earnings
Evolus, Inc. (EOLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.10+28.6%
$0.14
Rev
$73M+0.8%
$73M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.04-26.3%
$0.06
Rev
$90M+0.9%
$90M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.14+26.3%
$0.19
Rev
$69M-23.0%
$90M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.24-166.7%
$0.09
Rev
$69M-18.7%
$85M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.10vs $0.14+28.6% | $73Mvs $73M+0.8% |
| Q2 2026 | Mar 3, 2026 | $0.04vs $0.06-26.3% | $90Mvs $90M+0.9% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.19+26.3% | $69Mvs $90M-23.0% |
| Q3 2025 | Aug 5, 2025 | $0.24vs $0.09-166.7% | $69Mvs $85M-18.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Evolus, Inc. (EOLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.94 | $457.03M | -8.68 | 11.61% | -17.38% | — | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $1.11 | $143.86M | -6.94 | -10.02% | -2.03% | -9.41% | — | |
| $14.54 | $921.24M | 10.17 | -6.16% | 23.27% | 13.28% | — | |
| $9.60 | $2.09B | 9.14 | 20.19% | 10.37% | 241.47% | — |
Compare EOLS vs Peers
Evolus, Inc. (EOLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EOLS SEC Filings & Documents
Evolus, Inc. (EOLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EOLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EOLS Frequently Asked Questions
Evolus, Inc. (EOLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Evolus, Inc.'s revenue?
Evolus, Inc. (EOLS) reported $301.4M in revenue for fiscal year 2025.
How fast is Evolus, Inc. growing?
Evolus, Inc. (EOLS) grew revenue by 11.6% over the past year. This is steady growth.
Is EOLS profitable?
Evolus, Inc. (EOLS) reported a net loss of $43.4M for fiscal year 2025.
Dividend & Returns
What is Evolus, Inc.'s free cash flow?
Evolus, Inc. (EOLS) had negative free cash flow of $41.3M in fiscal year 2025, likely due to heavy capital investments.